US pharma group says region’s use of ‘one-way insurance system’ to keep down prices is not fair on the industry ...

Trump administration pressure on Big Pharma to focus investment on the US has raised concerns in Europe, and specifically the ...

Eli Lilly invests $3B in a Netherlands plant to produce obesity drug orforglipron, creating new jobs. Read more here.

Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the ...

Eli Lilly plans to build a $3 billion manufacturing facility in the Netherlands to expand its capacity to produce oral medicines. The pharmaceutical company said Monday that the new facility will be ...

Along with the company’s investment plans in Puerto Rico, Lilly also announced plans to build a $5 billon manufacturing plant ...

The Indianapolis-based pharmaceutical company said the new site will manufacture its weight-loss pill, orforglipron, and ...

The facility is expected to produce oral medications, including Lilly's highly anticipated GLP-1 pill for weight loss, orforglipron.

Eli Lilly shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion.

Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its keenly watched weight-loss pill, orforglipron, and other ...

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply ...

During the industry’s onshoring rush of the last nine months, Eli Lilly has been among the most aggressive biopharma compa | Eli Lilly is allotting $3 billion to establish an oral medicines ...